Am J Hematol. 2024 Jun 10. doi: 10.1002/ajh.27405. Online ahead of print.
NO ABSTRACT
PMID:38856232 | DOI:10.1002/ajh.27405
Recent Content
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML
- (no title)
- Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- (no title)
- Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
- Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression